Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
Last trade$689.35
Day change-$1.985 (-0.29%)
Day range$683.29 – $694.97
Volume650,332
Market cap$256.15B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$256.15B
Price / earnings
36.22×
Price / book
4.68×
Price / sales
5.41×
EV / sales
6.17×
EV / EBITDA
24.4×
Profitability
Earnings per share
$19.09
Return on assets
6.19%
Return on equity
12.91%
Dividend yield
0.26%
Liquidity and leverage
Debt / equity
0.76×
Current ratio
1.81×
Quick ratio
1.41×
Cash ratio
0.39×
Cash flow
Price / cash flow
27.47×
Price / free cash flow
33.72×
Free cash flow
$7.6B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TMO, quarterly periods
Line item
Q3 FY2026 Sep 26, 2026
Q2 FY2026 Jun 27, 2026
Q1 FY2026 Mar 28, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 27, 2025
Q2 FY2025 Jun 28, 2025
Q1 FY2025 Mar 29, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$12.14B
$11.99B
$11.01B
$12.22B
$11.12B
$10.86B
$10.36B
$11.4B
Cost of revenue
$7.01B
$7.11B
$6.58B
$7.2B
$6.54B
$6.45B
$6.13B
$6.57B
Gross profit
$5.13B
$4.88B
$4.43B
$5.01B
$4.58B
$4.41B
$4.24B
$4.82B
Selling, general and administrative
$2.32B
$2.33B
$2.18B
$2.35B
$2.16B
$2.14B
$2.08B
$2.2B
Research and development
$348M
$364M
$336M
$356M
$346M
$352M
$342M
$374M
Total operating expenses
$2.87B
$2.8B
$2.57B
$2.76B
$2.64B
$2.58B
$2.52B
$2.81B
Operating income
$2.26B
$2.09B
$1.86B
$2.26B
$1.94B
$1.83B
$1.72B
$2.02B
Interest expense
-$417M
-$401M
-$354M
-$365M
-$347M
-$404M
-$303M
-$317M
Income before taxes
$2.08B
$1.91B
$1.73B
$2.15B
$1.83B
$1.71B
$1.62B
$1.94B
Income taxes
$352M
$167M
$70M
$153M
$207M
$92M
$95M
$150M
Net income
$1.73B
$1.74B
$1.66B
$1.97B
$1.62B
$1.62B
$1.51B
$1.82B
Net income attributable to common shareholders
$1.72B
$1.74B
$1.65B
$1.96B
$1.62B
$1.62B
$1.51B
$1.83B
EBITDA
$4.2B
$2.09B
$2.65B
$3.03B
$3.6B
$1.74B
$2.52B
$2.99B
Basic earnings per share
$4.65
$4.68
$4.44
$5.25
$4.28
$4.28
$3.99
$4.79
Diluted earnings per share
$4.64
$4.68
$4.43
$5.21
$4.27
$4.28
$3.98
$4.80
Recent news
Company coverage with links to the original publishers.
Abbott reported strong mid-to-high-teens EP sales growth globally and over 20% in the U.S., driven by accelerating Volt PFA catheter adoption following its August launch. The company received FDA approval for TactiFlex Duo and CE Mark for Amulet 360, expanding treatment options. However, LAA market weakness is creating headwinds as customers delay purchases awaiting the new Amulet 360 device. Abbott expects Japan's Q4 Volt launch to provide growth momentum.
The global cell lysis and cell fractionation market is projected to grow from $2.8 billion in 2025 to $4.5 billion by 2032, expanding at a 7% CAGR. Growth is driven by advances in biotechnology, personalized medicine, proteomics, genomics research, and biopharmaceutical development. Emerging technologies including automation, microfluidics, AI/ML integration, and single-cell analysis capabilities are reshaping the market landscape.
The global nucleic acid labeling market is projected to grow from $1.7 billion in 2025 to $2.8 billion by 2032, expanding at a 7% CAGR. Growth is driven by advances in genomics, molecular diagnostics, NGS, and high-throughput laboratory workflows. Key applications include oligonucleotide labeling and in-situ hybridization, with the U.S. and China representing major regional markets.
A $1,000 investment in Thermo Fisher Scientific made in November 2016 would be worth $4,734.73 as of November 2, 2026, representing a 373.47% gain that significantly outperformed the S&P 500's 256.47% return. The company benefits from recovering pharma and biotech spending, expanded capabilities through acquisitions, and AI-enabled workflows, though academic spending remains subdued and competition poses ongoing challenges.
Zacks highlights strong stock performance across its various investment portfolios in early November 2026. Marathon Petroleum gained 14.71% following a Zacks Rank upgrade, while Chevron and Cheniere Energy surged 22.5% and 28% respectively over 12 weeks. Amgen returned 20.2% over the same period as investors favor quality dividend stocks amid market volatility. The article showcases performance of Zacks' rating systems including the Rank #1 portfolio, Focus List, and specialized portfolios like ECAP and ECDP.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$0.47 per share
Declared
Nov 5, 2026
Ex-dividend
Dec 15, 2026
Pay date
Jan 15, 2027
Ex-dividend
Amount / share
Pay date
Type
Sep 15, 2026
$0.47
Oct 15, 2026
recurring
Jun 15, 2026
$0.47
Jul 15, 2026
recurring
Mar 13, 2026
$0.47
Apr 15, 2026
recurring
Dec 15, 2025
$0.43
Jan 15, 2026
recurring
Sep 15, 2025
$0.43
Oct 15, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.